Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
June 07, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
April 25, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
March 31, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
February 02, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
January 26, 2023 08:30 ET
|
Artelo Biosciences
CEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26,...
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 08:00 ET
|
Artelo Biosciences
Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End $19.5 Million in Cash and Investments as of September 30, 2022 SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo...
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
September 22, 2022 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
August 16, 2022 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...